Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Formula rebounds, Amerifit grows in Martek Q2

This article was originally published in The Tan Sheet

Executive Summary

The infant formula market's rebound from 2009 lows helps boost Martek Biosciences' total product sales 35.1 percent to $119.1 million in the February-April period. Second-quarter sales of Martek's formula ingredients reached $86.3 million, up 11.5 percent, helped by gains in Asia, executives said June 3. Amerifit Brands, which Columbia, Md.-based Martek acquired in January, generated $18 million in revenue and $1.9 million in operating income. Martek plans to launch finished supplement products through Amerifit in 2011 (1"The Tan Sheet" Jan. 25, 2010). Additionally, the company continues seeking new applications for its algal life'sDHA. Martek announced June 2 the omega-3 ingredient will fortify sauces and dressings at sandwich chain Quiznos
Advertisement

Related Content

Martek Pursues Direct Consumer Access With Pending Acquisition Of Amerifit
Martek Pursues Direct Consumer Access With Pending Acquisition Of Amerifit

Topics

Advertisement
UsernamePublicRestriction

Register

PS104180

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel